newsfilter
← Latest News
GlobeNewswire·

Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

– Phase 1 monotherapy expansion study of micvotabart pelidotin (MICVO) for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients progressing well with preliminary data in second half of